Increasing Living Donor Liver Transplantation Using Liver Paired Exchange.


Journal

Journal of the American College of Surgeons
ISSN: 1879-1190
Titre abrégé: J Am Coll Surg
Pays: United States
ID NLM: 9431305

Informations de publication

Date de publication:
01 Feb 2022
Historique:
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 5 3 2022
Statut: ppublish

Résumé

Living donor liver transplantation (LDLT) continues to be the primary modality of liver transplantation in Asia, but it accounts for about 5% of all liver transplantations in the US. ABO incompatibility is the primary reason motivated donors are declined. Although kidney paired exchanges are common, liver paired exchange (LPE) is still evolving in the US. This is a retrospective review (between January 1, 2019, and July 31, 2021) of our initial experience with LPE. A total of 10 LPEs (20 LDLTs) were performed during the study period. Seven LPEs were initiated by a nondirected O donor. The other 3 pair sets involved 1 ABO compatible and 1 ABO incompatible pair. Transplantations in a pair set were completed within a mean of 4.8 (range 1-14) days of each other. All 20 donors are doing well with no major complications at 12.7 (range 1-20) months. Seventeen of 20 recipients are alive and have good allograft function. One recipient died in the early postoperative period. Two late deaths of patients with functioning allografts were due to COVID-19 (at 8 months) and peritoneal carcinomatosis and gram-negative sepsis (at 9 months). LPE is feasible in a high-volume LDLT center and is a useful option to increase LDLT by overcoming ABO incompatibility. Nondirected donors can be utilized to initiate an LPE.

Sections du résumé

BACKGROUND BACKGROUND
Living donor liver transplantation (LDLT) continues to be the primary modality of liver transplantation in Asia, but it accounts for about 5% of all liver transplantations in the US. ABO incompatibility is the primary reason motivated donors are declined. Although kidney paired exchanges are common, liver paired exchange (LPE) is still evolving in the US.
STUDY DESIGN METHODS
This is a retrospective review (between January 1, 2019, and July 31, 2021) of our initial experience with LPE.
RESULTS RESULTS
A total of 10 LPEs (20 LDLTs) were performed during the study period. Seven LPEs were initiated by a nondirected O donor. The other 3 pair sets involved 1 ABO compatible and 1 ABO incompatible pair. Transplantations in a pair set were completed within a mean of 4.8 (range 1-14) days of each other. All 20 donors are doing well with no major complications at 12.7 (range 1-20) months. Seventeen of 20 recipients are alive and have good allograft function. One recipient died in the early postoperative period. Two late deaths of patients with functioning allografts were due to COVID-19 (at 8 months) and peritoneal carcinomatosis and gram-negative sepsis (at 9 months).
CONCLUSIONS CONCLUSIONS
LPE is feasible in a high-volume LDLT center and is a useful option to increase LDLT by overcoming ABO incompatibility. Nondirected donors can be utilized to initiate an LPE.

Identifiants

pubmed: 35213430
doi: 10.1097/XCS.0000000000000036
pii: 00019464-202202000-00003
doi:

Substances chimiques

ABO Blood-Group System 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-120

Informations de copyright

Copyright © 2022 by the American College of Surgeons. Published by Wolters Kluwer Health, Inc. All rights reserved.

Références

Organ Procurement and Transplantation Network (OPTN). Available at: https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/# Accessed August 9, 2021.
Berg CL, Merion RM, Shearon TH, et al. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology. 2011;54:1313–1321.
Chan SC, Fan ST, Liu CL, et al. Working up donors for high-urgency and elective adult-to-adult live donor liver transplantation. Liver Transpl. 2007;13:509–515.
Mishra A, Lo A, Lee GS, et al. Liver paired exchange: Can the liver emulate the kidney? Liver Transpl. 2018;24:677–686.
Hwang S, Lee SG, Moon DB, et al. Exchange living donor liver transplantation to overcome ABO incompatibility in adult patients. Liver Transpl. 2010;16:482–490.
Chan SC, Lo CM, Yong BH, et al. Paired donor interchange to avoid ABO-incompatible living donor liver transplantation. Liver Transpl. 2010;16:478–481.
Patel MS, Mohamed Z, Ghanekar A, et al. Living donor liver paired exchange: a North American first. Am J Transplant. 2021;21:400–404.
Braun HJ, Torres AM, Louie F, et al. Expanding living donor liver transplantation: report of first US living donor liver transplant chain. Am J Transplant. 2020;00:1–4.
Klair T, Halff G, Fritze D, et al. Liver paired exchange using compatible pairs - US single center experience. Ann Surg. 2020;272:e282–e283.
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–196.
Baker A, Dhawan A, Devlin J, et al. Assessment of potential donors for living related liver transplantation. Br J Surg. 1999;86:200–205.
Sharma A, Ashworth A, Behnke M, et al. Donor selection for adult-to-adult living donor liver transplantation: well begun is half done. Transplantation. 2013;95:501–506.
Trotter JF, Wisniewski KA, Terrault NA, et al.; A2ALL Study Group. Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology. 2007;46:1476–1484.
Cowan N, Gritsch HA, Nassiri N, et al. Broken chains and reneging: a review of 1748 kidney paired donation transplants. Am J Transplant. 2017;17:2451–2457.
Ross LF, Woodle ES. Ethical issues in increasing living kidney donations by expanding kidney paired exchange programs. Transplantation. 2000;69:1539–1543.
Jung DH, Hwang S, Ahn CS, et al. Section 16. Update on experience in paired-exchange donors in living donor liver transplantation for adult patients at ASAN Medical Center. Transplantation. 2014;97(Suppl 8):S66–S69.
Garratty G, Glynn SA, McEntire R; Retrovirus Epidemiology Donor Study. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion. 2004;44:703–706.
Gentry SE, Segev DL, Simmerling M, et al. Expanding kidney paired donation through participation by compatible pairs. Am J Transplant. 2007;7:2361–2370.
Raza MH, Aziz H, Kaur N, et al. Global experience and perspective on anonymous nondirected live donation in living donor liver transplantation. Clin Transplant. 2020;34:e13836.

Auteurs

Vikraman Gunabushanam (V)

From the Division of Transplant Surgery (Gunabushanam, Ganoza, Molinari, Tevar, Hughes, Humar), University of Pittsburgh Medical Center, Pittsburgh, PA.

Swaytha Ganesh (S)

Division of Hepatology (Ganesh), University of Pittsburgh Medical Center, Pittsburgh, PA.

Kyle Soltys (K)

Division of Pediatric Transplant Surgery, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA (Soltys, Mazariegos).

George Mazariegos (G)

Division of Pediatric Transplant Surgery, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA (Soltys, Mazariegos).

Armando Ganoza (A)

From the Division of Transplant Surgery (Gunabushanam, Ganoza, Molinari, Tevar, Hughes, Humar), University of Pittsburgh Medical Center, Pittsburgh, PA.

Michele Molinari (M)

From the Division of Transplant Surgery (Gunabushanam, Ganoza, Molinari, Tevar, Hughes, Humar), University of Pittsburgh Medical Center, Pittsburgh, PA.

Amit Tevar (A)

From the Division of Transplant Surgery (Gunabushanam, Ganoza, Molinari, Tevar, Hughes, Humar), University of Pittsburgh Medical Center, Pittsburgh, PA.

Christopher Hughes (C)

From the Division of Transplant Surgery (Gunabushanam, Ganoza, Molinari, Tevar, Hughes, Humar), University of Pittsburgh Medical Center, Pittsburgh, PA.

Abhinav Humar (A)

From the Division of Transplant Surgery (Gunabushanam, Ganoza, Molinari, Tevar, Hughes, Humar), University of Pittsburgh Medical Center, Pittsburgh, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH